Ph.D, M. Pharm., B. Pham.

Dr. Kaladhar Kamalasanan joined as Assistant Professor in the Department of Pharmaceutics, Amrita School of Pharmacy in September 2015. He has 12 years research experience. He has last served as Fellow Scientist –D at Sree Chitra Tirunal Institute for Medical Sciences and Technology, India and is currently consulting for various organizations nationally and internationally.

He has more than three years of post doctoral research experience in USA from one of premier research groups in immunotherapeutics and drug delivery, Mc Gowan Institute for Regenerative Medicine; Department of Chemical Engineering, Bioengineering & Immunology, University of Pittsburgh, USA as well as he was a visiting scholar to Phillipps University, Marburg in Germany for 2 years.

He has completed Ph. D. in Biomedical Engineering (Biosurface Modification), Biomedical Technology Division, Sree Chitra Tirunal Institute for Medical Sciences and Technology. He has also done his M. Pharm. at Annamali University, Tamil Nadu and Bachelor of Pharmacy at Dr. MGR University, Tamil Nadu.

He has developed products filed several national and international patents, bagged several awards and has several research articles, book chapters and conference proceedings. He also actively participate in various professional society activities.



Publication Type: Journal Article

Year of Publication Title


A. Sasikumar and Dr. Kaladhar Kamalasanan, “Nanomedicine for prostate cancer using nanoemulsion: A review.”, J Control Release, vol. 260, pp. 111-123, 2017.[Abstract]

Prostate cancer (PCa) is a worldwide issue, with burgeoning rise in prevalence, morbidity and mortality. Targeted drug delivery, a long sort solution in this regard using controlled release (CR) - nanocarriers, is still a challenge. There is an emerging criticism that, the challenges are due to less appreciation for the biological barriers and lack of corresponding newer technologies. Over the years, more understanding about the biological barriers has come with the progress in characterization techniques. Correspondingly, there is a change in opinion about approaches in clinical trial that; focus of the end point need to be shifted towards disease stabilization for these explorative technologies. Currently, there is a requirement to overcome these newly identified challenges to develop newer affordable therapeutics. The ongoing clinical protocol for therapy using CR-nanocarriers is intravenous injection followed by local targeting to cancer site. This is the most accepted protocol and new CR-nanocarriers are being developed to suit this protocol. In this review, recent progress in treatment of PCa using CR-nanocarriers is analyzed with respect to newly identified biological barriers and design challenges. Possibilities of exploring nanoemulsion (NE) platform for targeted drug delivery to PCa are examined. Repurposing of drugs and combination therapy using NE platform targeted to PCa can be explored for design and development of affordable nanomedicine. In 20yrs. from now there expected to be numerous affordable nanomedicine technologies available in market exploring these lines.

More »»


A. S. Kumar, Kuruvila, T., Kavya, S. G., Radhakrishnan, R., Nair, A. J., and Dr. Kaladhar Kamalasanan, “Early detection of seizures in epilepsy using point of care (POC) systems”, Journal of Pharmaceutical Sciences and Research, vol. 9, pp. 302-306, 2017.[Abstract]

In epileptic patients recurrence of seizure is a concern and its prognosis is important. Getting seizure freedom is necessary for the patients to maintain a normal risk free life. Even though, the pharmacological treatment provides 60-70% reduction in seizures over prolonged treatment, the concerns of recurrence remains. In this review we are analysing the common psychological and physiological complications associated with epilepsy. Also analysing the use of point of care (POC) systems for seizure prognosis. In addition, the future possibilities for developing indigenous affordable and accessible technologies for seizure prognosis are analysed. © 2017, Pharmainfo Publications. All rights reserved.

More »»


J. P.V, Shantikumar V Nair, and Dr. Kaladhar Kamalasanan, “Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes”, Colloids and Surfaces B: Biointerfaces, vol. 153, pp. 123-131, 2017.[Abstract]

Diabetes mellitus (DM) is a metabolic disorder due to irregularities in glucose metabolism, as a result of insulin disregulation. Chronic DM (Type 1) is treated by daily insulin injections by subcutaneous route. Daily injections cause serious patient non-compliance and medication non-adherence. Insulin Depots (ID) are parenteral formulations designed to release the insulin over a specified period of time, to control the plasma blood glucose level for intended duration. Physiologically, pancreas produces and secretes insulin in basal and pulsatile mode into the blood. Delivery systems mimicking basal release profiles are known as open-loop systems and current marketed products are open-loop systems. Future trend in open-loop systems is to reduce the number of injections per week by enhancing duration of action, by modifying the depot properties. The next generation technologies are closed-loop systems that mimic the pulsatile mode of delivery by pancreas. In closed-loop systems insulin will be released in response to plasma glucose. This review focuses on future trend in open-loop systems; by understanding (a) the secretion of insulin from pancreas, (b) the insulin regulation normal and in DM, (c) insulin depots and (d) the recent progress in open-loop depot technology particularly with respect to nanosystems. © 2017 Elsevier B.V.

More »»


Dr. Kaladhar Kamalasanan, Renz, H., and Sharma, C. P., “Cell-mimetic coatings for immune spheres”, Colloids and Surfaces B: Biointerfaces, vol. 123, pp. 845–851, 2014.[Abstract]

Extrinsically induced or engineered cells are providing new therapeutic means in emerging fields such as cell therapeutics, immunomodulation and regenerative medicine. We are demonstrating a spatial induction method using lipid coatings, which can change signal presentation strength from material surface to adherent macrophage cells, that induce early cell–cell interaction leading to organotypic morphology. For that, we have developed a cell mimetic lipid coating with a rafts size to the order of transmembrane proteins (<10 nm) with enhanced lateral elastic properties. Such surface coatings are capable of reducing adherent macrophage spreading, while enabling early induction of cell–cell interaction to form organotypic macrophage colonies or “spheres” (M-spheres).

More »»


Dr. Kaladhar Kamalasanan, Gottardi, R., Tan, S., Chen, Y., Godugu, B., Rothstein, S., Balazs, A. C., Star, A., and Little, S. R., ““Zero-Dimensional” Single-Walled Carbon Nanotubes”, Angewandte Chemie International Edition, vol. 52, no. 43, pp. 11308–11312, 2013.[Abstract]

The shorter, the more dispersible: An iterative, emulsion-based shortening technique has been used to reduce the length of single-walled carbon nanotubes (SWNTs) to the same order of magnitude as their diameter (ca. 1 nm), thus achieving an effectively “zero-dimensional” structure with improved dispersibility and, after hydroxylation, long-term water solubility. Finally, zero-dimensional SWNTs were positively identified using mass spectrometry for the first time.

More »»


Dr. Kaladhar Kamalasanan, Jhunjhunwala, S., Wu, J., Swanson, A., Gao, D., and Little, S. R., “Patchy, Anisotropic Microspheres with Soft Protein Islets”, Angewandte Chemie International Edition, vol. 50, no. 37, pp. 8706–8708, 2011.[Abstract]

Useful contacts: A new method to achieve regular patterns generates anisotropic, “patchy” microspheres by using interfacial condensation of a liquid mask and the proximity of the particles to their neighbors to determine a mask pattern. The microspheres are separated from the scaffold and labeled with a first protein at non-mask regions (green) followed by removal of the mask and immobilization of a second protein (red).

More »»


S. C. Basak, Dr. Kaladhar Kamalasanan, and Subburaj, T., “Doxycycline hyclate delayed release capsules with sodium starch glycolate as a pH-dependent pore forming agent”, Indian journal of pharmaceutical sciences, vol. 66, pp. 704–707, 2004.[Abstract]

Delayed release doxycycline hyclate capsules were prepared with suitable blend of doxycycline hyclate-coated nonpareil seed pellets and doxycycline hyclate delayed release pellets. The delayed release pellets were prepared by coating the doxycycline hyclate-coated pellets with hydroxypropylmethylcellulose phthalate-55 polymer solution. A concentration of polymer in the range of 15 to 20% was found to comply with drug release test as specified in the USP in acid medium but failed to meet the requirements in buffer medium (pH 5.5). The inclusion of sodium starch glycolate (1-3%) in both doxycycline-coated and delayed release pellets preparation stages was found to enhance the release of the drug in the buffer medium without altering its release in acid medium. The blend of delayed release pellets (75%) and drug-coated pellets (25%) in delayed release doxycycline hyclate capsules produced an optimum in vitro drug release in both the media.

More »»